Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells

The present study explored the impact of two novel criteria; having >95% abnormal plasma cells by flow cytometry at diagnosis and the evolving subtype of the disease, as predictors of progression in 61 smouldering multiple myeloma (SMM) and 311 monoclonal gammopathy of unknown significance (MGUS) patients. Although both criteria were of prognostic value, the risk of progression was better identified by immunophenotyping [Hazard Ratio (HR) 6·2 and 17·2 for SMM and MGUS, respectively] than evolving subtype, which had independent prognostic value only in MGUS (HR 3·6). Immunophenotyping discriminated the different risk of progression within the evolving and non‐evolving subgroups of SMM (P = 0·01) and MGUS (P < 0·001).

[1]  A. Órfão,et al.  Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. , 2008, Blood.

[2]  Marina Ruggeri,et al.  Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders , 2008, Haematologica.

[3]  A. Órfão,et al.  New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. , 2007, Blood.

[4]  J. Esteve,et al.  Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma , 2005, British journal of haematology.

[5]  E. Giné,et al.  Smoldering multiple myeloma: natural history and recognition of an evolving type , 2003, British journal of haematology.

[6]  Kenneth C. Anderson,et al.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.

[7]  C. Klersy,et al.  Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  G. Morgan,et al.  Minimal residual disease monitoring in multiple myeloma. , 2002, Best practice & research. Clinical haematology.

[9]  A. Órfão,et al.  Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. , 2002, Blood.

[10]  Terry M Therneau,et al.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance. , 2002, The New England journal of medicine.

[11]  Joan,et al.  Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. , 1998, The American journal of pathology.

[12]  M. Dimopoulos,et al.  Prognostic features of asymptomatic multiple myeloma , 1997, British journal of haematology.

[13]  H. Asaoku,et al.  Phenotypic difference of normal plasma cells from mature myeloma cells. , 1993, Blood.

[14]  A. Órfão,et al.  Multiparameter flow cytometry remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation , 2008 .

[15]  J. F. San Miguel Izquierdo,et al.  Immunophenotyping of plasma cells in multiple myeloma. , 2005, Methods in molecular medicine.

[16]  S. Rajkumar,et al.  MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management. , 2005, Hematology. American Society of Hematology. Education Program.

[17]  Gema Mateo Manzanera,et al.  Immunophenotyping of Plasma Cells in Multiple Myeloma , 2005 .